Referanslar

1. Coppola C, Greco M, Munir A, Musarò D, Quarta S, Massaro M et al. Osteoarthritis: Insights into Diagnosis, Pathophysiology, Therapeutic Avenues, and the Potential of Natural Extracts. Curr Issues Mol Biol. 2024;46:4063-105. [Crossref]  [PubMed]  [PMC]
2. Basedow M, Runciman WB, March L, Esterman A. Australians with osteoarthritis; the use of and beliefs about complementary and alternative medicines. Complement Ther Clin Pract. 2014;20:237-42. [Crossref]  [PubMed]
3. Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52:167-75. [Crossref]  [PubMed]
4. ALPTEKİN DÖ. Glukozamin ve Kondroitin Sülfatın Osteoartrit Tedavisindeki Etkinliği. Turkiye Klinikleri Journal of Medical Sciences. 2009;29:1687-94. [Link]
5. Monfort J, Carné X, Abarca B, Giménez S, Romera M, Möller I et al. Experts document about an adequate utilization of SYSADOAs in controversial clinical situations. Reumatol Clin (Engl Ed). 2021;17:595-600. [Crossref]  [PubMed]
6. Colletti A, Cicero AFG. Nutraceutical Approach to Chronic Osteoarthritis: From Molecular Research to Clinical Evidence. Int J Mol Sci. 2021;22. [Crossref]  [PubMed]  [PMC]
7. Uitterlinden EJ, Jahr H, Koevoet JL, Jenniskens YM, Bierma-Zeinstra SM, Degroot J et al. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage. 2006;14:250-7. [Crossref]  [PubMed]
8. Persiani S, Rotini R, Trisolino G, Rovati LC, Locatelli M, Paganini D et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage. 2007;15:764-72. [Crossref]  [PubMed]
9. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;2005:Cd002946. [Crossref]  [PubMed]  [PMC]
10. Zhu X, Wu D, Sang L, Wang Y, Shen Y, Zhuang X et al. Comparative effectiveness of glucosamine, chondroitin, acetaminophen or celecoxib for the treatment of knee and/ or hip osteoarthritis: a network meta-analysis. Clin Exp Rheumatol. 2018;36:595-602. [PubMed]
11. Wandel S, Jüni P, Tendal B, Nüesch E, Villiger PM, Welton NJ et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. Bmj. 2010;341:c4675. [Crossref]  [PubMed]  [PMC]
12. Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum. 2007;56:2267-77. [Crossref]  [PubMed]
13. Katz JN, Arant KR, Loeser RF. Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. Jama. 2021;325:568-78. [Crossref]  [PubMed]  [PMC]
14. Bichsel D, Liechti FD, Schlapbach JM, Wertli MM. Cross-sectional Analysis of Recommendations for the Treatment of Hip and Knee Osteoarthritis in Clinical Guidelines. Arch Phys Med Rehabil. 2022;103:559-69.e5. [Crossref]  [PubMed]
15. Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49:337-50. [Crossref]  [PubMed]
16. Kubo M, Ando K, Mimura T, Matsusue Y, Mori K. Chondroitin sulfate for the treatment of hip and knee osteoarthritis: current status and future trends. Life Sci. 2009;85:477-83. [Crossref]  [PubMed]
17. Conte A, Volpi N, Palmieri L, Bahous I, Ronca G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung. 1995;45:918-25. [PubMed]
18. Reichenbach S, Sterchi R, Scherer M, Trelle S, Bürgi E, Bürgi U et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146:580-90. [Crossref]  [PubMed]
19. Zhu X, Sang L, Wu D, Rong J, Jiang L. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2018;13:170. [Crossref]  [PubMed]  [PMC]
20. Lila AM, Alekseeva LI, Baranov AA, Taskina EA, Kashevarova NG, Lapkina NA et al. Chondroitin sulfate and glucosamine combination in patients with knee and hip osteoarthritis: A long-term observational study in Russia. World J Orthop. 2023;14:443-57. [Crossref]  [PubMed]  [PMC]
21. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J et al. 2019 American College of Rheumatology/ Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72:149-62. [Crossref]  [PubMed]  [PMC]
22. Zhang W, Doherty M. EULAR recommendations for knee and hip osteoarthritis: a critique of the methodology. Br J Sports Med. 2006;40:664-9. [Crossref]  [PubMed]  [PMC]
23. Bello AE, Oesser S. Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature. Curr Med Res Opin. 2006;22:2221-32. [Crossref]  [PubMed]
24. García-Coronado JM, Martínez-Olvera L, Elizondo-Omaña RE, Acosta-Olivo CA, Vilchez-Cavazos F, Simentaal-Mendía LE et al. Effect of collagen supplementation on osteoarthritis symptoms: a meta-analysis of randomized placebo-controlled trials. Int Orthop. 2019;43:531-8. [Crossref]  [PubMed]
25. Puigdellívol Grifell J, Comellas Berenguer C, Steinbacher G, Kranjcec T, Álvarez Díaz P, López Pujol A et al. Open, Observational, Single-Arm, Multicenter Study Assessing the Effectiveness of a Dietary Supplement Containing Hydro- lyzed Collagen, Chondroitin Sulfate, and Glucosamine for Osteoarthritis Pain Reduction. J Diet Suppl. 2024;21:374-88. [Crossref]  [PubMed]
26. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SM et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27:1578-89. [Crossref]  [PubMed]
27. Salehi B, Rescigno A, Dettori T, Calina D, Docea AO, Singh L, et al. Avocado-Soybean Unsaponifiables: A Panoply of Potentialities to Be Exploited. Biomolecules. 2020;10. [Crossref]  [PubMed]  [PMC]
28. Simental-Mendía M, Sánchez-García A, Acosta-Olivo CA, Vilchez-Cavazos F, Osuna-Garate J, Peña-Martínez VM et al. Efficacy and safety of avocado-soybean unsaponifiables for the treatment of hip and knee osteoarthritis: A systematic review and meta-analysis of randomized placebo-controlled trials. Int J Rheum Dis. 2019;22:1607-15. [Crossref]  [PubMed]
29. Maheu E, Mazières B, Valat JP, Loyau G, Le Loët X, Bourgeois P et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, place- bo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum. 1998;41:81-91. [Crossref]
30. Maheu E, Cadet C, Marty M, Moyse D, Kerloch I, Coste P et al. Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis. 2014;73:376-84. [Crossref]  [PubMed]  [PMC]
31. Angermann P. [Avocado/soybean unsaponifiables in the treatment of knee and hip osteoarthritis]. Ugeskr Laeger. 2005;167:3023-5. [PubMed]
32. Moe RH, Haavardsholm EA, Christie A, Jamtvedt G, Dahm KT, Hagen KB. Effectiveness of nonpharmacological and nonsurgical interventions for hip osteoarthritis: an umbrella review of high-quality systematic reviews. Phys Ther. 2007;87:1716-27. [Crossref]  [PubMed]
33. Olivier P, Montastruc JL. [Post-marketing safety profile of avocado-soybean unsaponifiables]. Presse Med. 2010;39:e211-6. [Crossref]  [PubMed]
34. Martínez-Abundis E, González-Ortiz M, Mercado-Sesma AR, Reynoso-von-Drateln C, Moreno-Andrade A. Effect of avocado soybean unsaponifiables on insulin secretion and insulin sensitivity in patients with obesity. Obes Facts. 2013;6:443-8. [Crossref]  [PubMed]  [PMC]
35. Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moça Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014;2014:Cd005117. [Crossref]  [PubMed]  [PMC]
36. Karateev AE, Alekseeva LI, Pogozheva EY, Amirdzhanova VN, Filatova ES, Nesterenko VA et al. [Efficacy of combined use of glycosaminoglycan peptide complex for intramuscular administration and oral diacerein in osteoarthritis: evaluation according to an observational multicenter clinical trial]. Ter Arkh. 2021;93:71513. [Crossref]  [PubMed]
37. Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med. 2006;166:1899-906. [Crossref]  [PubMed]
38. Pavelka K, Bruyère O, Cooper C, Kanis JA, Leeb BF, Maheu E et al. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging. 2016;33:75-85. [Crossref]  [PubMed]  [PMC]
39. Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. BMC Musculoskelet Disord. 2004;5:6. [Crossref]  [PubMed]  [PMC]
40. Rutjes AW, Nüesch E, Reichenbach S, Jüni P. S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2009;2009:Cd007321. [Crossref]  [PubMed]
41. Hosea Blewett HJ. Exploring the mechanisms behind S-adenosylmethionine (SAMe) in the treatment of osteoarthritis. Crit Rev Food Sci Nutr. 2008;48:458-63. [Crossref]  [PubMed]
42. Soeken KL, Lee WL, Bausell RB, Agelli M, Berman BM. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract. 2002;51:425-30. [PubMed]
43. SAM-e. Drugs and Lactation Database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development; 2006. [PubMed]
44. De Silva V, El-Metwally A, Ernst E, Lewith G, Macfarlane GJ. Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review. Rheumatology (Oxford). 2011;50:911-20. [Crossref]  [PubMed]
45. Usha PR, Naidu MU. Randomised, Double-Blind, Parallel, Placebo-Controlled Study of Oral Glucosamine, Methylsulfonylmethane and their Combination in Osteoarthritis. Clin Drug Investig. 2004;24:353-63. [Crossref]  [PubMed]
46. Kim SM, Jo SY, Park HY, Lee YR, Yu JS, Yoo HH. Inves- tigation of Drug-Interaction Potential for Arthritis Dietary Supplements: Chondroitin Sulfate, Glucosamine, and Methylsulfonylmethane. Molecules. 2023;28. [Crossref]  [PubMed]  [PMC]
47. Swallow J, Seidler K, Barrow M. The mechanistic role of curcumin on matrix metalloproteinases in osteoarthritis. Fitoterapia. 2024;174:105870. [Crossref]  [PubMed]
48. Bideshki MV, Jourabchi-Ghadim N, Radkhah N, Behzadi M, Asemani S, Jamilian P et al. The efficacy of curcumin in relieving osteoarthritis: A meta-analysis of meta-analyses. Phytother Res. 2024;38:2875-91. [Crossref]  [PubMed]
49. Mathieu S, Soubrier M, Peirs C, Monfoulet LE, Boirie Y, Tournadre A. A Meta-Analysis of the Impact of Nutritional Supplementation on Osteoarthritis Symptoms. Nutrients. 2022;14. [Crossref]  [PubMed]  [PMC]
50. Zeng L, Yu G, Hao W, Yang K, Chen H. The efficacy and safety of Curcuma longa extract and curcumin supplements on osteoarthritis: a systematic review and meta-analysis. Biosci Rep. 2021;41. [Crossref]  [PubMed]  [PMC]
51. Rohdewald PJ. Review on Sustained Relief of Osteoarthritis Symptoms with a Proprietary Extract from Pine Bark, Pycnogenol. J Med Food. 2018;21:1-4. [Crossref]  [PubMed]  [PMC]
52. Paramdeep G. Efficacy and tolerability of ginger (Zingiber officinale) in patients of osteoarthritis of knee. Indian J Physiol Pharmacol. 2013;57:177-83. [PubMed]
53. Zeng Y, Yu S, Lu L, Zhang J, Xu C. Ginger-derived nanovesicles attenuate osteoarthritis progression by inhibiting oxidative stress via the Nrf2 pathway. Nanomedicine (Lond). 2024;19:2357-73. [Crossref]  [PubMed]
54. Drozdov VN, Kim VA, Tkachenko EV, Varvanina GG. Influence of a specific ginger combination on gastropathy conditions in patients with osteoarthritis of the knee or hip. J Altern Complement Med. 2012;18:583-8. [Crossref]  [PubMed]
55. Conrozier T, Renevier JL, Parisaux JM, Balblanc JC. Pre- dictive factors of adherence to an association of glucos- amine sulfate, copper, and ginger extracts in patients with symptomatic osteoarthritis: a prospective open-label French noninterventional study (the PREDOA study). Patient Prefer Adherence. 2019;13:915-21. [Crossref]  [PubMed]  [PMC]
56. Bartels EM, Folmer VN, Bliddal H, Altman RD, Juhl C, Tarp S et al. Efficacy and safety of ginger in osteoarthritis patients: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage. 2015;23:13-21. [Crossref]  [PubMed]
57. Chevalley T, Brandi ML, Cashman KD, Cavalier E, Harvey NC, Maggi S et al. Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Os- teoporosis, Osteoarthritis and Musculoskeletal Diseases (ES- CEO) working group. Aging Clin Exp Res. 2022;34:2603-23. [Crossref]  [PubMed]  [PMC]
58. Park CY. Vitamin D in the Prevention and Treatment of Osteoarthritis: From Clinical Interventions to Cellular E idence. Nutrients. 2019;11. [Crossref]  [PubMed]  [PMC]
59. Bergink AP, Trajanoska K, Uitterlinden AG, van Meurs JBJ. Mendelian randomization study on vitamin D levels and osteoarthritis risk: a concise report. Rheumatology (Oxford). 2021;60:3409-12. [Crossref]  [PubMed]
60. Veronese N, Maggi S, Noale M, De Rui M, Bolzetta F, Zambon S et al. Serum 25-Hydroxyvitamin D and Osteoarthritis in Older People: The Progetto Veneto Anziani Study. Rejuvenation Res. 2015;18:543-53. [Crossref]  [PubMed]
61. Cordingley DM, Cornish SM. Omega-3 Fatty Acids for the Management of Osteoarthritis: A Narrative Review. Nutrients. 2022;14. [Crossref]  [PubMed]  [PMC]
62. Gross BW, Gillio M, Rinehart CD, Lynch CA, Rogers FB. Omega-3 Fatty Acid Supplementation and Warfarin: A Lethal Combination in Traumatic Brain Injury. J Trauma Nurs. 2017;24:15-8. [Crossref]  [PubMed]
63. Li X, Lu Z, Qi Y, Chen B, Li B. The Role of Polyunsaturated Fatty Acids in Osteoarthritis: Insights from a Mendelian Randomization Study. Nutrients. 2023;15. [Crossref]  [PubMed]  [PMC]
64. Gruenwald J, Petzold E, Busch R, Petzold HP, Graubaum HJ. Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis. Adv Ther. 2009;26:858-71. [Crossref]  [PubMed]
65. Jacquet A, Girodet PO, Pariente A, Forest K, Mallet L, Moore N. Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial. Arthritis Res Ther. 2009;11:R192. [Crossref]  [PubMed]  [PMC]
66. Gibbs AJ, Gray B, Wallis JA, Taylor NF, Kemp JL, Hunter DJ et al. Recommendations for the management of hip and knee osteoarthritis: A systematic review of clinical practice guidelines. Osteoarthritis Cartilage. 2023;31:1280-92. [Crossref]  [PubMed]
67. Jüni P, Hari R, Rutjes AWS, Fischer R, Silletta MG, Reiche bach S et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database of Systematic Reviews. 2015. [Crossref]  [PubMed]  [PMC]
68. Cemil Ertürk AÖ, Halil Büyükdoğan. Intra-articular injection applications in the treatment of osteoarthritis: Corticosteroid, hyaluronic acid and collagen. TOTBİD Dergisi 2022;21:508-514. 2022. [Crossref]
69. Lei T, Wang Y, Li M, Hua L. Clinical efficacy of multiple intra-articular injection for hip osteoarthritis. Bone Joint J. 2024;106-b:532-9. [Crossref]  [PubMed]
70. Nicholas E, Cheng J, Moley PJ. Non-operative Treatment Options for Osteoarthritis in the Hip. Hss j. 2023;19:486-93. [Crossref]  [PubMed]  [PMC]
71. Richard MJ, Driban JB, McAlindon TE. Pharmaceutical treatment of osteoarthritis. Osteoarthritis Cartilage. 2023;31:458-66. [Crossref]  [PubMed]
72. Sanguino RA, Sood V, Santiago KA, Cheng J, Casey E, Mintz D et al. Prevalence of rapidly progressive osteo- arthritis of the hip following intra-articular steroid injections. Pm r. 2023;15:259-64. [Crossref]  [PubMed]  [PMC]
73. Angotti ML, Burnett RA, Khalid S, Terhune EB, Della Valle CJ. Intra-articular corticosteroids associated with increased risk of total hip arthroplasty at 5 years. Hip Int. 2023;33:800-5. [Crossref]  [PubMed]
74. Micu MC, Micu A, Bolboacă SD. Ultrasound-guided injection with hyaluronic acid in hip osteoarthritis: efficacy and safety in a real-life setting. Clin Rheumatol. 2022;41:2491-8. [Crossref]  [PubMed]
75. Patel R, Orfanos G, Gibson W, Banks T, McConaghie G, Banerjee R. Viscosupplementation with High Molecular Weight Hyaluronic Acid for Hip Osteoarthritis: a Systematic Review and Meta-Analysis of Randomised Control Trials of the Efficacy on Pain, Functional Disability, and the Occurrence of Adverse Events. Acta Chir Orthop Traumatol Cech. 2024;91:109-19. [Crossref]  [PubMed]
76. Zhu J, Lim A, McCaskie AW, Khanduja V. Viscosupplementation Is Effective for the Treatment of Osteoarthritis in the Hip: A Systematic Review. Arthroscopy. 2024;40:1908-22. e13. [Crossref]  [PubMed]
77. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72:220-33. [Crossref]  [PubMed]  [PMC]
78. Le ADK, Enweze L, DeBaun MR, Dragoo JL. Current Clinical Recommendations for Use of Platelet-Rich Plasma. Curr Rev Musculoskelet Med. 2018;11:624-34. [Crossref]  [PubMed]  [PMC]
79. Lim A, Zhu JB, Khanduja V. The Use of Intra-articular Platelet-Rich Plasma as a Therapeutic Intervention for Hip Osteoarthritis: A Systematic Review and Meta-analysis. Am J Sports Med. 2023;51:2487-97. [Crossref]  [PubMed]  [PMC]
80. Sambe HG, Yasir M, Man RK, Gogikar A, Nanda A, Janga LSN et al. Comparing Intra-articular Platelet-Rich Plasma With Hyaluronic Acid for the Treatment of Hip Osteoarthritis: A Systematic Review and Meta-Analysis. Cureus. 2023;15:e47919. [Crossref]  [PubMed]
81. Mardones R, Jofré CM, Tobar L, Minguell JJ. Mesenchymal stem cell therapy in the treatment of hip osteoarthritis. J Hip Preserv Surg. 2017;4:159-63. [Crossref]  [PubMed]  [PMC]
82. Entessari M, Oliveira LP. Current evidence on mesenchymal stem cells for hip osteoarthritis: a narrative review. Regen Med. 2023;18:749-58. [Crossref]  [PubMed]
83. Giorgino R, Alessandri Bonetti M, Migliorini F, Nannini A, Vaienti L, Peretti GM et al. Management of hip osteoarthritis: harnessing the potential of mesenchymal stem cells-a systematic review. Eur J Orthop Surg Traumatol. 2024. [Crossref]  [PubMed]  [PMC]
84. Waluyo Y, Artika SR, Insani Nanda W, Gunawan A, Zainal ATF. Efficacy of Prolotherapy for Osteoarthritis: A Systematic Review. J Rehabil Med. 2023;55:jrm00372. [Crossref]  [PubMed]  [PMC]
85. Gül D, Orsçelik A, Akpancar S. Treatment of Osteoarthritis Secondary to Developmental Dysplasia of the Hip with Prolotherapy Injection versus a Supervised Progressive Exercise Control. Med Sci Monit. 2020;26:e919166. [Crossref]  [PubMed]  [PMC]